Eberhard Grube, MD

Country Germany
Specialty Interventional Cardiologist
  1. AS Lifetime Management
  2. EVOLUT: New Trials, New Technologies (OPTIMIZE PRO and SMART)
  3. TAVR is Better
  4. How to Prevent TAVR Complications with New TAVR Devices
  5. Next Innovation in Transcatheter Valve Intervention: New Techniques and New Valves
  6. Optimal TAVR Procedure for Bicuspid AV: Self Expandable Device
  7. Novel Implant Techniques: What is Different?
  8. Minimizing Embolic Events: Latest TAVR Data
  9. The Next Target of the Valvular Intervention: Future Perspectives
  10. Mitral Valve-in-Valve and Valve-in-Ring: Outcomes and Procedural Considerations
  11. Percutaneous Mitral Valve Repair: Current Status and Future Perspectives
  12. Future Perspectives for TAVR - What Is Remained?
  13. TAVR in 2019: Appropriate Patient and Device Selection
  14. Evolut PRO Latest Innovation in TAVI: A Workhorse Device to Treat All Patient
  15. Cerebral Protection in TAVR: Which Patient Category or Anatomical Subset?
  16. Next Generation TAVR Devices
  17. TAVR Will Be a New Standard Even for Low-risk Patients
  18. Cerebral Embolic Protection: Routine or Selective
  19. MitraClip and TMVR Complications and Failures
  20. Cerebral Protection Device During TAVI: State of the Art
  21. TAVR vs SAVR in 2018: Updated Guidelines and Appropriate Use Criteria
  22. Rapid Changing TAVR Story: Predicting the Future from Ongoing TAVR Clinical Trials
  23. European Registry
  24. Severe Calcification: Avoid or Overcome
  25. Coronary or Cerebral Protection: When and How?
  26. Complex TAVR for Specific Challenging Cases - How to Do in Practice?
  27. New Mainstream TAVR
  28. TAVR of High-Risk/Complex Patients: For Whom and with?
  29. Building Evidence for Treating Lower Risk Patients: Recent Updates From Evolut R Technology and Evidence
  30. [Featured Lecture] \"TAVI Perspective 2017: Current Situation - Controversy - Prospect\"
  31. SURTAVI: Step-by-Step Moving Forward to Low Risk and Younger Patients
  32. Evolut R
  33. Ongoing TAVR Trials and Updating TAVR Guidelines
  34. Cerebral Embolic Protection During TAVR
  35. Update on Medtronic Intrepid Transcatheter Mitral Valve Replacement
  36. Monitoring Conduction Disturbance and Avoiding Permanent Pacemaker
  37. TAVR in Lower Risk
  38. Evolut R
  39. Evolving Trends in Complications After TAVR
  40. How Evolut R Has Impacted My Practice?
  41. Mechanical Expanded Lotus Valve
  42. Do We Need a Dedicated Bifurcation Stent or Is This a Niche Device?
  43. Next Generation Valve System Addressing Current TAVR Limitations
  44. Why I Select Self Expandable Valve.
  45. Valve in Valve Implants for Failed Bioprosthetic Heart Valves
  46. Ultimate Comparison: Sapien vs. Corevalve
  47. Which TAVI Devices to Use: A Multi-Device Patient-Specific Approach
  48. Stroke Prevention: When and How
  49. Boston Lotus: Transfemoral
  50. Beyond the First-generation Devices
  51. European Registry: Sapien vs. Core
  52. New TAVI Devices
  53. Beyond High-risk Patients: Will TAVR Replace Surgical AVR?
  54. Registry Results of Self-expandable CoreValve Studies
  55. Dedicated Bifurcation Stent
  56. New TAVI Systems
  57. Medtronic: CoreValve Evolut and Engager TAVI System
  58. European Outcomes of CoreValve Registry
  59. Durability of Sapien Valve and CoreValve
  60. Taped Lives: Implantation of CoreValve, Transaxilla or Transaortic
  61. Technology and Procedural Changes
  62. Core Valve Enough !
  63. Upcoming New Devices
  64. Alternative Approach with Core Valve: Transaxillary and Others
  65. Implantation: Rapid Pacing, Pre-and Post-dilation
  66. Taped Live Case: Core Valve 2
  67. TAVI; Evidence, Controversy, Complications, and Future Perspective
  68. Invited Case Presentation & Focus Review: Aortic Valve Intervention(Core Valve)
  69. Taking DES Technology from Concept to Clinical Proof
  70. Which One Is Better?- Edwards or CoreValve or Others?: CoreValve Is Better!
  71. Valve-in-Valve TAVI
  72. Case Selection for TAVR: Beyond the High-risk Patient
  73. Evidence Based Medicine: Does BioMatrixTM Bring Patient Benefit? - 3 Yr/Subgroup Follow Up from LEADERS Trial
  74. Case Presentation of the First Restenosed Core Valve Prosthesis: Treatment Solution!
  75. BIOFREEDOM: Polymer-Free Biolimus A9-Eluting Stents and Paclitaxel-Eluting Stents
  76. Incidence and Treatment of Procedural Complications
  77. TAVI Perspectives from the European Theatre: New Indications and Multiple Devices
  78. Pitfalls During the TAVI (Core Valve) Implantation and How to Treat Them\".
  79. Dedicated Bifurcation and Left Main Stents
  80. An Update of the Self Expanding Medtronic/Core Valve TAVI
  81. The Core Valve Experience from the Siegburg Heart Center. An Update.
  82. New TAVI Devices: More of the Same or Meaningful Differences?
  83. Next Generation on PAVR Technologies
  84. New Approach to Treating Thrombus- Containing Lesions
  85. Interventionalist Perspective: The Treatment Pathway Was Shifted !
  86. New Stent Platforms
  87. Update on the Core Valve Experience
  88. The Future Landscape of DES: New Stent Platforms, Drug Carriers, and Recent FIM Experiences
  89. Percutaneous Aortic Valve Implantation
  90. Drug Eluting Stents (Bifurcation and Left Main Approach)
  91. The Xtent™ DES System: The Single Solution for Multilesion, Multivessel, and Long Lesion Treatment
  92. Biolimus A9 Drug-Eluting Stents: Technical Aspects and a Comprehensive Review of the EU, Asia-Pacific, and US NOBORI Clinical Trial Program
  93. Current Data Indicates No Clinically Relevant Differences Between CYPHER and TAXUS!
  94. Everolimus Drug-Eluting Stents I: Review of Guidant FUTURE I and II, and Status Update of FUTURE III and IV
  95. The Biolimus A9 DES Program (Focus on Stealth 1)
  96. Is the TAXUS Stent Benefit Extended to the Most Complicated Patients and Lesions?
  97. New Drug-Eluting Stents: Everolimus (FUTURE-I and -II) and More